The reports that the expression of p-SMAD2 is associated with malignant phenotype and poor prognosis in patients with advanced GC [33] and that high TGFβ-SMAD activity confers poor prognosis in patients with glioma [32] support the promotional effect of SMAD2 on GC progression. Here, SMAD2 is linked to central nervous system cancer.